CEO TarGlio (The Collider Programme)

Job description

TARGLIO | Nanoparticles for Glioblastoma Targeting & Magnetic Hyperthermia CEO & Co-Founder Opportunity | DeepTech | Nanomedicine | Oncology Are you ready to build a high-impact deep-tech spin-off addressing aggressive and lethal brain tumors? TARGLIO is developing magnetic nanoparticles engineered to efficiently cross the blood–brain barrier (BBB) and enable targeted glioblastoma therapy through MRI-guided magnetic hyperthermia. The technology has been validated at TRL 4 , including preliminary preclinical studies in glioblastoma models. We are looking for an entrepreneurial CEO to lead the creation of the spin-off and drive regulatory, preclinical, fundraising and partnering strategy. About TARGLIO: While nanomedicine has emerged as a promising field, most nanotherapeutics fail because they cannot efficiently cross the BBB and achieve effective tumor targeting. TARGLIO has developed iron-oxide magnetic nanoparticles (NPs) functionalized with a glucose derivative that leverages the overexpression of GLUT transporters in tumor vasculature. Why TARGLIO: Your Role as CEO & Co-Founder (Next 6 Months) - Unique capacity to cross the tumor BBB after intravenous administration , overcomin...